Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528308 | 0.92 | HRH3 (0.39) | HRH3MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26531165 | 0.90 | HRH3 (0.40) | HRH3MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26531176 | 0.85 | TDP1 (0.48) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL26528040 | 0.85 | L3MBTL1 (0.43) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL26528088 | 0.82 | TRPA1 (0.38) | HRH3MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26528097 | 0.79 | MEN1 (0.37) | HRH3MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23528574 | 0.77 | TDP1 (0.49) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL23528277 | 0.77 | L3MBTL1 (0.45) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL26531183 | 0.77 | L3MBTL1 (0.48) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL26528018 | 0.76 | L3MBTL1 (0.48) | MEN1KMT2AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | HRH3 3219/4885MEN1 4467/4885KMT2A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.